首页> 外文期刊>Therapeutic Drug Monitoring >Interference of endogenous digoxin-like immunoreactive factors in serum digoxin measurement is minimized in a new turbidimetric digoxin immunoassay on ADVIA 1650 analyzer.
【24h】

Interference of endogenous digoxin-like immunoreactive factors in serum digoxin measurement is minimized in a new turbidimetric digoxin immunoassay on ADVIA 1650 analyzer.

机译:在ADVIA 1650分析仪上进行的新型比浊地高辛免疫测定中,将内源性地高辛样免疫反应因子对血清地高辛测量的干扰降至最低。

获取原文
获取原文并翻译 | 示例
       

摘要

Endogenous digoxin-like immunoreactive factors (DLIF) cross-react with antidigoxin antibody and falsely elevate or lower measured serum digoxin concentrations, depending on the assay design. Recently, Bayer Diagnostics released a turbidimetric assay for digoxin on the ADVIA 1650 analyzer. We studied potential interference of DLIF with this new digoxin assay. We analyzed 40 serum specimens from patients who have pathologic conditions that may increase serum DLIF concentrations. These patients were never exposed to digoxin or other agents that may lead to a measurable digoxin concentration. We also analyzed five specimens from autopsy and five specimens from neonates. Apparent digoxin concentrations were measured using the new turbidimetric digoxin assay, the fluorescence polarization immunoassay (FPIA, Abbott Laboratories, Abbott Park, IL), and also the chemiluminescent immunoassay (CLIA, Bayer Diagnostics). We observed measurable apparent digoxin levels with the FPIA in 5 uremic patients (range 0.24-0.86 ng/mL), 6 patients with liver disease (range 0.21-0.72 ng/mL), in 3 patients in the third trimester of pregnancy (0.21-26 ng/mL), and in 3 neonates (range 0.21-0.46 ng/mL). Four out of 5 autopsy specimens showed measurable apparent digoxin concentrations (0.23-0.81 ng/mL). In contrast, only 1 specimen (a uremic patient) showed an apparent digoxin concentration of 0.26 ng/mL with the turbidimetric digoxin immunoassay (FPIA value 0.86 ng/mL, CLIA value 0.32 ng/mL). Because DLIF is absent in the protein-free ultrafiltrate, we also measured free digoxin concentrations in DLIF-positive patients to ensure that the apparent digoxin concentrations were caused by DLIF. We observed no apparent digoxin concentrations in the protein-free ultrafiltrate in any DLIF-positive specimens. When serum specimens containing elevated concentrations of DLIF but no digoxin were supplemented with a known concentration of digoxin, we observed falsely elevated digoxin concentrations by the FPIA, as expected. In contrast, we observed a good agreement between the target and observed concentrations when the new turbidimetric assay was used. We conclude that DLIF has minimal effect on serum digoxin measurements by the new turbidimetric assay.
机译:内源性地高辛样免疫反应因子(DLIF)与抗地高辛抗体发生交叉反应,并根据检测设计错误地升高或降低了血清地高辛的浓度。最近,Bayer Diagnostics在ADVIA 1650分析仪上发布了地高辛比浊测定法。我们用这种新的地高辛试验研究了DLIF的潜在干扰。我们分析了来自患有可能会增加血清DLIF浓度的病理状况的患者的40个血清标本。这些患者从未接触过地高辛或可能导致可测量地高辛浓度的其他药物。我们还分析了五个尸检标本和五个新生儿标本。使用新的浊度地高辛测定法,荧光偏振免疫测定法(FPIA,雅培实验室,伊利诺伊州艾伯特公园)以及化学发光免疫测定法(CLIA,Bayer Diagnostics)来测定表观地高辛浓度。我们观察到5例尿毒症患者(范围0.24-0.86 ng / mL),6例肝病患者(范围0.21-0.72 ng / mL),3例妊娠晚期(0.21-0.21 ng / mL)的FPIA可测量的地高辛水平26 ng / mL)和3例新生儿(范围0.21-0.46 ng / mL)。 5个尸检标本中有4个显示出可测量的地高辛表观浓度(0.23-0.81 ng / mL)。相比之下,仅1个标本(尿毒症患者)通过比浊地高辛免疫测定法(FPIA值为0.86 ng / mL,CLIA值为0.32 ng / mL)显示出地高辛的表观浓度为0.26 ng / mL。由于无蛋白质的超滤液中不含DLIF,因此我们还测量了DLIF阳性患者的游离地高辛浓度,以确保表观地高辛浓度是由DLIF引起的。我们在任何DLIF阳性标本中的无蛋白超滤液中均未观察到明显的地高辛浓度。当含有高浓度DLIF但无地高辛的血清标本中添加了已知浓度的地高辛时,我们发现FPIA会错误地升高地高辛的浓度,这与预期的一样。相反,当使用新的浊度测定法时,我们观察到目标浓度与观察到的浓度之间有很好的一致性。我们得出结论,通过新的比浊法,DLIF对血清地高辛的测量影响最小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号